

ANEXO B**1. Name**

Vianey González-Villasana

Education – degree, discipline, institution, year

Degree	Discipline	Institution	Year	Country
PhD	In science with orientation in Biotechnology	Universidad Autónoma de Nuevo León	2012	Mexico
BS	Chemistry Bacteriology Parasitology	Universidad Autónoma de Nuevo León	2004	Mexico

Academic experience – institution, rank, title (chair, coordinator, etc. if appropriate), date (ex. 1990-1995), full time or part time

Institution	Title	Date	Responsibility
Universidad Autónoma de Nuevo Leon	Full Professor	2015	Teaching Genetic and Molecular Biology, Advisor, thesis committee member

Non-academic experience – company or entity, title, brief description of position, when (ex. 1993-1999), full time or part time

Company or entity	Title	Brief description of position	Date	Responsibility
University of Texas M. D. Anderson Cancer Center	Postdoctoral Fellow	Full time research	2012-2014	Work in design, planning and perform research projects as well as writing and publish the results of our research Training graduate and summer students in research Attend a conference to show our research results

				Attend weekly seminars Attend courses or trainings Present our data in a weekly Postdoctoral meetings
University of Texas M. D. Anderson Cancer Center	Research Assistant I	Assistance in research projects	2008-2012	Participate in research projects by planning and perform experiments, collaborate, collaborate in research projects, prepare solutions, ordering reagents

Certifications or professional registrations

Certifications/Professional registrations	Institution	Date	Status
N/A	N/A	N/A	N/A

Current membership in professional organizations

Professional Organization	Title	Date	Status

Honors and awards

Title	Institution	Date	Status
Magna Cum Laude	Universidad Autónoma de Nuevo León	2012	

Service activities (within and outside of the institution)

Activity	Institution	Date	Status

Briefly list the most important publications and presentations from the past five years—title, co-authors, if any, place of publication or presentation, and date of publication or presentation

[The ZNF304-integrin axis protects against anoikis in cancer.](#)

Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein. Nat Commun. 2015 Jun 17;6:7351. doi: 10.1038/ncomms8351

[Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.](#)

Armaiz-Pena GN, Gonzalez-Villasana V, Nagaraja AS, Rodriguez-Aguayo C, Sadaoui NC, Stone RL, Matsuo K, Dalton HJ, Previs RA, Jennings NB, Dorniak P, Hansen JM, Arevalo JM, Cole SW, Lutgendorf SK, Sood AK, Lopez-Berestein G. Oncotarget. 2015 Feb 28;6(6):4266-73.

[Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer.](#)

Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, Aslan B, Monroig-Bosque PD, Velazquez-Torres G, Previs RA, Pradeep S, Kahraman N, Wang H, Kanlikilicer P, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Clin Cancer Res. 2015 Jan 16. pii: clincanres.2279.2014.

[Therapeutic silencing of KRAS using systemically delivered siRNAs.](#)

Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Mol Cancer Ther. 2014 Dec;13(12):2876-85. doi: 10.1158/1535-7163.MCT-14-0074. Epub 2014 Oct 3.

[Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.](#)

Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E, Deng D, Hwang RF, Wang H, Ivan C, Garza RJ, Cohen E, Gao H, Armaiz-Pena GN, Del C Monroig-Bosque P, Philip B, Rashed MH, Aslan B, Erdogan MA, Gutierrez-Puente Y, Ozpolat B, Reuben JM, Sood AK, Logsdon C, Lopez-Berestein G. Mol Cancer Ther. 2014 Nov;13(11):2583-94. doi: 10.1158/1535-7163.MCT-14-0028.

[Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.](#)

Reusser NM, Dalton HJ, Pradeep S, Gonzalez-Villasana V, Jennings NB, Vasquez HG, Wen Y, Rupaimoole R, Nagaraja AS, Gharpure K, Miyake T, Huang J, Hu W, Lopez-Berestein G, Sood AK. Cancer Biol Ther. 2014 Aug;15(8):1061-7. doi: 10.4161/cbt.29184. Epub 2014 May 19.

[Monocyte subpopulations in angiogenesis.](#)

Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Cancer Res. 2014 Mar 1;74(5):1287-93. Doi: 10.1158/0008-5472.CAN-13-

2825. Epub 2014 Feb 20. Review.

[Tumour angiogenesis regulation by the miR-200 family.](#) Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Nat Commun. 2013;4:2427. doi: 10.1038/ncomms3427.

[Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.](#) Gonzalez-Villasana V, Gutiérrez-Puente Y, Tari AM. Oncol Rep. 2013 Sep;30(3):1506-10. doi: 10.3892/or.2013.2549. Epub 2013 Jun 19.

[Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.](#)

Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G. Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

[Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion.](#)

González-Villasana V, Nieves-Alicea R, McMurtry V, Gutiérrez-Puente Y, Tari AM. Oncol Rep. 2012 Mar;27(3):861-6. doi: 10.3892/or.2011.1600. Epub 2011 Dec 21. PMID: 22200873

Briefly list the most recent professional development activities

Professional Activity	Date
1 Researcher	2012
2 Full Professor	2015
3 Reviewer Journal BioMed Central Cancer (BMC Cancer)	2015
4 Associate Editor Journal Nanomedicine & Nanotechnology Open Access (NNOA)	2016
5 Advisor	2015
6	
7	
8	
9	
10	
ETC....	